Moberg Pharma Faces Financial Struggles Amid Strategic Success with Terclara
Moberg Pharma AB reports significant financial decline in Q2 2025, but CEO cites success of flagship product Terclara and strategic focus on European markets as reasons for hope.
3 minutes to read